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11received control (16331% vs 1314%, p¼0.001). The Figure shows T1-weighted MR
images and optical images below. Fluorescent microscopy demonstrated the presence
of green ﬂuorescence consistent with NBD-labeled liposomes within the infarct area
of hearts from mice that received liposomes while there was no green ﬂuorescence in
the hearts of mice that received injection of saline control.
CONCLUSIONS Following a murine model of MI, liposomes trafﬁc to the heart and
preferentially home to regions of myocardial injury. These liposomes can be loaded
with therapeutic agents to deliver novel agents directly to regions of myocardial
injury.TECHNOLOGY: RENAL DENERVATION
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AIM Renal denervation is an emerging technique for the treatment of patients with
drug-resistant hypertension. Long-term results using multi-electrode systems have
not been reported. We investigated the safety and efﬁcacy of the EnligHTN ablation
system developed by St. Jude Medical.
METHODS AND RESULTS The EnligHTN renal denervation system has 4 electrodes
attached on a basket mounted at the tip of the catheter. The basket is collapsed and
can be expanded via an external mechanism. The electrodes are then sequentially
activated to achieve the desired lesion pattern. The basket is then pulled back and
repositioned for a new set of lesions in order to optimize renal artery denervation.
The EnligHTN-I ﬁrst-in-human study was designed to assess the safety and efﬁcacy of
this multi-electrode ablation system in patients with drug-resistant hypertension. A
total of 46 patients (average age 6010yrs taking an average of 4.71.0 medications)were enrolled in this study. Of these patients 33% were female, 98% were white, 20%
had Coronary Artery Disease, 59% had hyperlipidemia, 33% had type II Diabetes
Mellitus, and 30% had history of sleep apnea. Bilateral renal nerve ablation was
performed using a percutaneous femoral approach. On average 7.70.8 lesions were
created in the right renal artery and 7.41.4 in the left renal artery. The median
procedure time was 34 minutes.
Baseline average ofﬁce blood pressure was 176/96 mmHg and average 24 hr
ambulatory blood pressure was 150/83 mmHg. Average reductions (mmHg) of ofﬁce
blood pressure at 1, 3, 6, 12, 18 and 24 months were -28/10, -27/10, -26/10, -27/11, -24/
10 and -29/13 mmHg (p<0.0001) respectively. For the 24hr ambulatory blood pressure
reductions at 1, 3, 6, and 12 was -9/5, -10/5, -10/6, -7/4 and -13/7 mmHg (p<0.0001 for
1,3,6 and 24 P<0.0094 for 12 months) respectively. At 24 months 77% of patients were
responders (at least 10 mmHg reduction in systolic blood pressure) and 39% had
normalized blood pressure (<140 mmHg systolic blood pressure). The study utilized
an independent Clinical Events Committee to adjudicate all adverse events. Based on
their adjudication, there were 4 device/procedure related serious adverse events in 3
subjects reported to date which include: hypertensive renal disease progression,
symptomatic hypotension, worsening of pre-existing renal artery stenosis and new
stenotic lesion.
CONCLUSIONS We conclude that data demonstrates that the EnligHTN ablation
system continues to be safe and effective in the treatment of patients with drug-
resistant hypertension.VALVE & STRUCTURAL HEART: AORTIC VALVE
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has being increasingly
offered in low and intermediate surgical risk patients with severe aortic stenosis (AS),
although the effectiveness of TAVR in this particular population has not been
demonstrated yet. This analysis aims to describe 1-year clinical outcomes of a large
series of propensity-matched patients at intermediate risk undergoing surgical aortic
valve replacement (SAVR) and transfemoral TAVR.
METHODS OBSERVANT is an observational prospective multicenter cohort study,
enrolling AS patients undergoing SAVR or TAVR. Propensity score method was
applied to select two groups with similar baseline characteristics. All outcomes were
adjudicated through a linkage with administrative databases. The primary end points
of the OBSERVANT study were death from any cause, and major adverse cardiac and
cerebrovascular events (MACCE) at 1 year. MACCE were deﬁned as the composite of
death from any cause, stroke, myocardial infarction, PCI and CABG. Prespeciﬁed
secondary end points included repeat hospitalization due to cardiac reasons and
acute heart failure have been analyzed.
RESULTS The unadjusted enrolled population (N¼7,618) comprises 5,707 SAVR pa-
tients and 1,911 TAVR patients. Matched population comprised a total of 1,300 pa-
tients (650 patients for each group). An intermediate risk population was selected
(mean logistic EuroSCORE 10.29.2% vs. 9.57.1%, SAVR vs. transfemoral TAVR;
p¼0.104). At 1-year, the rate of death from any cause was 13.6% in the surgical group
as compared with 13.8% in the transcatheter group (Hazard Ratio [HR]: 0.99, 95%
conﬁdence interval [CI], 0.72-1.35; p¼0.936). Similarly, there were no signiﬁcant
differences in the rates of MACCE between the two groups, which were 17.6% in the
surgical group as compared with 18.2% in the transcatheter group (HR: 1.03, 95%CI
0.78-1.36; p¼0.831). The cumulative incidence of cerebrovascular events, re-hospi-
talization due to cardiac reasons and due to acute heart failure, as assessed by
competing risk regression approach, was similar in both groups at 1 year.
CONCLUSION The results of this study on a large propensity-matched cohort of pa-
tients with severe AS and at intermediate surgical risk show that SAVR and trans-
femoral TAVR have comparable mortality, MACCE, and re-hospitalization due to
cardiac reasons rates at 1 year. These data need to be conﬁrmed at longer terms and by
dedicated ongoing randomized trials.
